VRDN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VRDN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Viridian Therapeutics's current ratio for the quarter that ended in Sep. 2024 was 18.55.
Viridian Therapeutics has a current ratio of 18.55. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Viridian Therapeutics's Current Ratio or its related term are showing as below:
During the past 12 years, Viridian Therapeutics's highest Current Ratio was 23.99. The lowest was 0.93. And the median was 7.80.
The historical data trend for Viridian Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viridian Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Current Ratio | Get a 7-Day Free Trial | 2.92 | 12.14 | 14.68 | 12.93 | 18.26 |
Viridian Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Current Ratio | Get a 7-Day Free Trial | 13.93 | 18.26 | 23.99 | 15.82 | 18.55 |
For the Biotechnology subindustry, Viridian Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Viridian Therapeutics's Current Ratio falls into.
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
Viridian Therapeutics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Current Ratio (A: Dec. 2023 ) | = | Total Current Assets (A: Dec. 2023 ) | / | Total Current Liabilities (A: Dec. 2023 ) |
= | 486.478 | / | 26.635 | |
= | 18.26 |
Viridian Therapeutics's Current Ratio for the quarter that ended in Sep. 2024 is calculated as
Current Ratio (Q: Sep. 2024 ) | = | Total Current Assets (Q: Sep. 2024 ) | / | Total Current Liabilities (Q: Sep. 2024 ) |
= | 767.357 | / | 41.364 | |
= | 18.55 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viridian Therapeutics (NAS:VRDN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Thank you for viewing the detailed overview of Viridian Therapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas W. Beetham | officer: Chief Operating Officer | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Stephen F. Mahoney | director, officer: President and CEO | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Fairmount Healthcare Fund Ii Gp Llc | director, other: See Remarks | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Fairmount Healthcare Fund Gp Llc | director, other: See Remarks | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Sarah Gheuens | director | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Seth Harmon | officer: See Remarks | C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 401, WALTHAM MA 02453 |
Lara Meisner | officer: General Counsel and Secretary | C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG. 17, SUITE 102, WALTHAM MA 02453 |
Scott Dunseth Myers | director, officer: Chief Executive Officer | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Jonathan Violin | officer: President and COO | 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087 |
Barrett Katz | officer: Chief Medical Officer | 6200 LOOKOUT ROAD, C/O MIRAGEN THERAPEUTICS, INC., BOULDER CO 80301 |
Carrie Melvin | officer: COO | C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG 17, SUITE 102B, WALTHAM MA 02453 |
Frazier Life Sciences Public Fund, L.p. | 10 percent owner | TWO UNION SQUARE, 601 UNION ST., SUITE 3200, SEATTLE WA 98101 |
Fhmlsp, L.l.c. | 10 percent owner | C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
L.p. Fhmlsp, | 10 percent owner | C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Kristian Humer | officer: CFO and CBO | C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301 |
From GuruFocus
By Business Wire • 11-05-2024
By GuruFocus Research • 09-18-2024
By Business Wire • 06-06-2024
By GuruFocus News • 11-15-2024
By Business Wire • 05-08-2024
By Business Wire • 04-29-2024
By Business Wire • 07-03-2024
By Business Wire • 05-31-2024
By Business Wire • 09-05-2024
By GuruFocus News • 11-15-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.